Companies Directory

Glx Services and Solutions nasce dalla collaborazione di professionisti specializzati in diversi settori dell'Information Technology. Avvalendoci delle esperienze pluriennali dei singoli collaboratori ci proponiamo di fornire soluzioni e servizi di alta qualità per tutte le aziende che vogliono restare al passo con il progresso tecnologico.

GLX helps Oil & Gas and Water Utility clients optimize operations through automation. Our field services and professional services divisions provide end-to-end solutions—from system design and field integration to final commissioning. We offer both application-specific builds and off-the-shelf control panels to meet diverse needs. By enabling real-time monitoring, control, and data visualization, we drive efficiency, cost reduction, and compliance. With a phased approach to automation, we empower clients to modernize at their own pace, ensuring flexibility, scalability, and long-term sustainability.

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!

Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mother's milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults. Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions. We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs. We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!

GlycoMark, Inc., a company based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. GlycoMark, Inc. is the exclusive supplier of the GlycoMark test in the United States, Europe, Australia, Asia-Pacific region and the Middle East. The GlycoMark test is used around the world to enhance the management of glycemic control in patients with diabetes, which has been diagnosed in nearly 10% of the U.S. population and costs the U.S. healthcare system over $325 billion per year.* The company possesses extensive resources to facilitate the discovery and commercialization of innovative biomarkers and new test methodologies for its product portfolio. GlycoMark, Inc. is jointly owned by New York Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan).

For more than 40 years, Glycon Corp. has focused on helping our customers to become better, more efficient processors. Our current family of advanced technologies are all designed specifically to improve throughput, increase quality, reduce scrap and streamline processing. Whether your application is simple or complex, we can help improve your machine efficiency, part quality and reliability. Product & Process Development As processors gear up for production on a new project, Glycon's dedicated Product Development Center has the resources to help optimize screw performance, testing several different designs and then zeroing in on the best melting and mixing combination. Or, if a molder is having a problem with splay or burning, or if an extruder is not getting proper mixing or sufficient throughput, technicians at the Center, can reproduce these problems under controlled conditions and quickly find ways to attack the problem through the application of the latest screw and processing technology. Rebuilding Services Glycon Corp. experts can help extend the life of costly meltstream components. Feedscrews can be rebuilt to match original performance specifications. Barrels can be re-sleeved to original dimensions. Other components, like our QSO non-return valve, can be rebuilt. All done quickly and with the highest standard of quality. Preventive Maintenance/Installation Glycon Corp. can assist with setup and maintenance of your feedscrew and related meltstream components. Our 10-Step Field Service Program streamlines setup and checks that your feedscrews are operating correctly. We can also design a maintenance program to reduce downtime and keep your systems operating as efficiently as the day they were installed. And we can train your maintenance personnel or implement the program ourselves. Contact Glycon at (800) 255-9969 for more information. Get a fast quote http://www.glycon.com/quote

GLYCONIC developed a unique biotechnological platform to selectively rhamnosylate natural compounds. The technology enables the efficient production of new rhamnosides, e.g. as active ingredients for cosmeceutical and nutraceutical applications.